A Multi-level Intervention to Increase Access and Use of the Patient Portal
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT05180721
- Status
- Completed
Conditions
- Diabetes Mellitus, Type 2
- Patient Education
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Use of patient portal for diabetes management — BEHAVIORALA multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
Study Details
The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
Key Dates
- Start date
- Oct 3, 2022
- Status verified
- Jun 2025
- Primary completion
- Jul 2, 2024
- Completion
- Jul 2, 2024
Study Design
- Enrollment
- 26 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Use of patient portal for diabetes managementA multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
Primary Outcome Measure
Usage of Portal [ Time Frame: Monthly for 6 months ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Fair Haven Community Health Center | New Haven | Connecticut | 06510 | - |
| Norwalk Community Health Center | Norwalk | Connecticut | 06854 | - |
Find similar trials in New Haven, CT
By condition
By specialty
Related Studies
- Diabetes Learning in Virtual Environments Just in Time for Community ReentryRecruiting · Louise Reagan · Storrs, Connecticut
- Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)Recruiting · Yale University · New Haven, Connecticut
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePHASE3 · Recruiting · Boehringer Ingelheim · Anniston, Alabama
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesPHASE3 · Not Yet Recruiting · Novo Nordisk A/S · New Haven, Connecticut